Open AccessClinical effectiveness and safety of low cost versus innovator brand amlodipine in hypertension: A single-blinded, randomized, crossover, noninferiority trial
Author(s) -
Alak Kumar Das,
Suparna Chatterjee,
Jyotirmoy Pal
Publication year - 2016
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.194844
Subject(s) - amlodipine , medicine , crossover study , blood pressure , confidence interval , randomized controlled trial , diastole , innovator , essential hypertension , placebo , alternative medicine , pathology , intellectual property , computer science , operating system
A single-blinded, randomized, crossover, noninferiority trial was conducted to evaluate clinical effectiveness and safety of low-cost brand (LCB) versus innovator brand (IB) amlodipine in essential hypertension.